Non-Alcoholic Steatohepatitis (NASH) Emerging and Marketed Drugs Assessment (2023 Updates) | Clinical and Non-Clinical Trials Evaluation, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Competitive Landscape, and Key Companies

Las Vega (Nevada), United States //— As per DelveInsight’s assessment, globally, about 100+ key pharma and biotech companies are working on 150+ pipeline drugs in the Non-Alcoholic Steatohepatitis therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

“Non-Alcoholic Steatohepatitis (NASH) Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Non-Alcoholic Steatohepatitis Market.

The Non-Alcoholic Steatohepatitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Non-Alcoholic Steatohepatitis (NASH) Pipeline Analysis
The report provides insights into:

– The report provides detailed insights about emerging therapies for the treatment of Non-Alcoholic Steatohepatitis and the aggregate therapies developed by major pharma companies.
– It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non-Alcoholic Steatohepatitis Treatment.
– It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
– The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
– It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Non-Alcoholic Steatohepatitis market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Delveinsight’s Report Covers Emerging Products Under Different Phases of Clinical Development Like –
– Late-stage products (Phase III)
– Mid-stage products (Phase II)
– Early-stage products (Phase I/II and Phase I)
– Pre-clinical and Discovery stage candidates
– Discontinued & Inactive candidates

Route of Administration
Nonalcoholic Steatohepatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
– Intra-articular
– Intraocular
– Intrathecal
– Intravenous
– Ophthalmic
– Oral
– Parenteral
– Subcutaneous
– Topical
– Transdermal

Molecule Type
Products have been categorized under various Molecule types, such as
– Oligonucleotide
– Peptide
– Small molecule

Non-Alcoholic Steatohepatitis (NASH) Therapeutics Landscape

There are approx. 130+ key companies are developing therapies for Nonalcoholic Steatohepatitis. Currently, Madrigal Pharmaceuticals is leading the therapeutics market with its Nonalcoholic Steatohepatitis drug candidates in the most advanced stage of clinical development.

Some of the key companies in the Non-Alcoholic Steatohepatitis (NASH) Therapeutics Market include:

Akero Therapeutics, Albireo Pharma, Allergan, Altimmune, Inc., Amgen, ARTham Therapeutics, Ascletis, AstraZeneca, Bird Rock Bio, Boston Pharmaceuticals, Bristol-Myers Squibb, Cascade Pharmaceuticals, Cerenis Therapeutics, Chipscreen Biosciences, Cirius Therapeutics, Conatus Pharmaceuticals, DURECT Corporation, Enanta Pharmaceuticals, Enzychem Lifesciences, Galecto Biotech, Galmed, Genfit, Gilead Sciences, Gmax Biopharm, GSK plc., Guangdong Zhongsheng Pharmaceutical, Hepion Pharmaceuticals, HighTide Biopharma, Ildong Pharmaceutical, InorbitTX, Intercept Pharmaceuticals, Ionis Pharmaceuticals, J2H Biotech, LG Chem Life sciences, Liminal BioSciences, Madrigal Pharmaceuticals, Melior Pharmaceuticals, Merck Sharp & Dohme LLC, NorthSea Therapeutics, Palobiofarma, Pharmaxis, Pliant Therapeutics, Rivus Pharmaceuticals, Sciwind Biosciences, SCOHIA PHARMA, TaiwanJ Pharmaceuticals, Thoth Science, Tiziana Life Sciences, TransThera Biosciences, Viking Therapeutics, and many others.

Non-Alcoholic Steatohepatitis (NASH) Therapies covered in the report include:

– Aramchol_005: Galmed
– Cenicriviroc: Allergan- Tobira
– EDP-305: Enanta Pharmaceuticals
– Elafibranor: Genfit
– Emricasan: Conatus Pharmaceuticals
– GS-9674: Gilead Sciences
– HTD 1801: HighTide Biopharma
– HU 6: Rivus Pharmaceuticals
– ION224: Ionis Pharmaceuticals
– MSDC-0602K: Cirius Therapeutics
– OCA: Intercept Pharmaceuticals
– Resmetirom: Madrigal Pharmaceuticals
– Selonsertib: Gilead Sciences
And many more

Explore More About the Emerging Drugs and Key Companies: Non-Alcoholic Steatohepatitis Pipeline Development Activities

Table of Content (TOC)

1. Report Introduction
2. Executive Summary
3. Non-Alcoholic Steatohepatitis Current Treatment Patterns
4. Non-Alcoholic Steatohepatitis – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Non-Alcoholic Steatohepatitis Late-Stage Products (Phase-III)
7. Non-Alcoholic Steatohepatitis Mid-Stage Products (Phase-II)
8. Non-Alcoholic Steatohepatitis Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Non-Alcoholic Steatohepatitis Discontinued Products
13. Non-Alcoholic Steatohepatitis Product Profiles
14. Key Companies in the Non-Alcoholic Steatohepatitis Market
15. Key Products in the Non-Alcoholic Steatohepatitis Therapeutics Segment
16. Dormant and Discontinued Products
17. Non-Alcoholic Steatohepatitis Unmet Needs
18. Non-Alcoholic Steatohepatitis Future Perspectives
19. Non-Alcoholic Steatohepatitis Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Get a Detailed Assessment into the Ongoing Clinical and Regulatory Development Activities, at: Non-Alcoholic Steatohepatitis Therapeutic Outlook

Contact Info:
Shruti Thakur
Manager (Marketing and Branding)
Email: info@delveinsight.com

Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic healthcare market today @ Healthcare Partner Identification Solutions

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.